Drug Profile
Radavirsen - Sarepta Therapeutics
Alternative Names: AVI-7100; AVI-7376Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator AVI BioPharma
- Developer National Institute of Allergy and Infectious Diseases; Sarepta Therapeutics
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action Genetic transcription inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza A virus infections
Most Recent Events
- 30 Dec 2022 Discontinued - Phase-I for Influenza A virus infections (In volunteers) in USA (IV)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Influenza-A-virus-infections(In volunteers) in USA (IV, Infusion)
- 02 Apr 2018 Phase-I development is still ongoing in Influenza-A-virus-infections(In volunteers) in USA (IV, Infusion)